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Isogenic iPS cells 
A B S T R A C T   
When studying patient specific induced pluripotent stem cells (iPS cells) as a disease model, the ideal control is 
an isogenic line that has corrected the point mutation, instead of iPS cells from siblings or other healthy subjects. 
However, repairing a point mutation in iPS cells even with the newly developed CRISPR-Cas9 technique remains 
difficult and time-consuming. Here we report a strategy that makes the Cas9 “knock-in” methodology both 
hassle-free and error-free. Instead of selecting a Cas9 recognition site close to the point mutation, we chose a site 
located in the nearest intron. We constructed a donor template with the fragment containing the corrected point 
mutation as one of the homologous recombination arms flanking a PGK-PuroR cassette. After selection with 
puromycin, positive clones were identified and further transfected with a CRE vector to remove the PGK-PuroR 
cassette. Using this methodology, we successfully repaired the point mutation G2019S of the LRRK2 gene in a 
Parkinson Disease (PD) patient iPS line and the point mutation R329H of the AARS1 gene in a Charcot-Marie- 
Tooth disease (CMT) patient iPS line. These isogenic iPS lines are ideal as a control in future studies.   
1. Introduction 
About half of the known human pathogenic genetic variants are 
point mutations (Anzalone et al., 2019) in which the disease gene only 
has one nucleotide difference in patients compared with that of healthy 
individuals. Thus, a strategy which uses an easy and reliable way to 
correct point mutations would represent a significant step forward. 
Recent developments in gene targeting techniques, especially CRISPR- 
Cas9, makes routine the repair of these genetic mutations (Protocols 
like in (Ran et al., 2013)). In such applications, synthesized single- 
stranded oligodeoxynucleotides (ssODN) as donor templates are most 
commonly used in homology-directed repair-based (HDR) knock-in for 
small repairs (Richardson et al., 2016). The knock-in efficiency has been 
shown to be higher when using ssODNs with the introduction of a silent 
mutation at the PAM site to prevent cutting on the edited allele (Arm-
strong et al., 2016). Also using asymmetric donor DNA can increase the 
HDR efficiency (Richardson et al., 2016). However, several obstacles 
still remain. First, finding suitable Cas9 cleavage sites is not always 
practical. The conventional CRISPR-Cas9 “knock-in” strategy usually 
requires that the selected cleavage site resides as close as possible to the 
mutation site to achieve higher efficiency (Bialk et al., 2015; Harmsen 
et al., 2018; Paquet et al., 2016). Secondly, while double-strand 
breakage has a higher efficiency of HDR than single-strand nicks, 
many non-homologous end joining (NHEJ) events happen during 
double-strand breakage. Moreover, using synthesized ssODN with short 
homologous arms produces more occurrences of insertions and deletions 
(indels) or point mutations compared to plasmid donor templates with 
long homologous arms (Elliott et al., 1998). Most critically, the effi-
ciency of homologous repair is still low even with the latest development 
of RNP (ribonucleoprotein: synthetic sgRNA and Cas9 recombinant 
protein complex) (Okamoto et al., 2019) when there is no reporter or 
selection cassettes. Finally, in order to identify positively targeted 
clones, it is necessary to sequence the genomic components of a large 
number of clones. 
To repair point mutations more efficiently, the Liu lab first developed 
the base editor using a catalytically impaired Cas protein (dCas or Cas 
nickase) connected with a DNA-modifying enzyme, a deaminase to make 
precise base substitution possible. After sgRNA directs dCas to the target 
site, without double-strand cleavage or donor template DNA, the 
deaminase modifies the base instead of Cas9 cleavage of the DNA 
(Komor et al., 2016). Current base editing techniques only allow base 
substitutions of C•G to T•A that is mediated by cytosine base editors 
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(CBEs), and base substitutions of A•T to G•C that is mediated by adenine 
base editors (ABEs). Consequently, the speed of base editing can be slow 
and the selection of the targeted site limited. 
Here, we apply the CRISPR-Cas9 technique to generate an isogenic 
line from the most common variant of LRRK2 gene in both familial and 
idiopathic PD patients (Goldwurm et al., 2005). This c.6055G > A point 
mutation changes Gly to Ser at 2019aa, increasing kinase activity of 
LRRK2 (West et al., 2005). It remains unclear why this activated form of 
LRRK2 is tightly associated with PD. In the last decades, iPS cell tech-
nology brought about a revolutionary change in human disease 
modeling. Thus, with the introduction of a combination of 3 or 4 tran-
scription factors, somatic cells can be transformed into stem cells with 
unlimited capacity for cell division and differentiation (Takahashi et al., 
2007). Reprogrammed patient cells can be used to explore disease 
mechanisms or screen for possible useful drug therapies. In these 
studies, the use of control isogenic cell lines derived from the same 
patient iPS cells is critical. Instead of designing the sgRNA recognition 
site close to the mutation site, we chose a location in the nearest intron 
that gives more flexibility to choose an optimal sgRNA location. Having 
the corrected sequence on one of the homologous arms, the mutated 
allele was repaired through homologous recombination. We also 
included a loxP flanked PGK-PuroR cassette so that after selection with 
puromycin, the efficiency of choosing positive clones would be much 
higher. With this new efficient strategy, we successfully obtained clones 
that have corrected the point mutation. Similarly, using this same gene 
editing strategy, we also efficiently repaired the c.986G > A point mu-
tation of AARS1 gene, which changes Arg to His at 329aa in familial 
CMT patients (McLaughlin et al., 2012). The AARS1 gene codes for the 
growth-dependent essential enzyme alanyl-tRNA synthetase, which 
catalyzes aminoacylation of tRNAAla with alanine to support translation 
of alanine codons during protein synthesis on the ribosome. The R329H 
mutation of AARS1 severely compromises the catalytic activity of the 
enzyme (McLaughlin et al., 2012), emphasizing the importance to study 
this mutation in the development of the CMT disease. 
2. Materials and methods 
2.1. Cell culture 
LRRK2 (ND40018*C) iPS cell line was obtained from NINDS human 
genetics DNA and cell line repository. Fibroblasts harboring the R329H 
AARS1 mutation were isolated from an anonymous patient in Australia 
through clinical collaboration with Dr. Michael Shy of University of 
Iowa, and were made into 100550A iPS cell line with mRNA reprog-
ramming kit (Stemgent). BJ fibroblast were obtained from ATCC (CRL- 
2522™) and reprogrammed with the same mRNA reprogramming kit. 
LRRK2 and BJ iPS cells were maintained in mTeSR1 medium (Stem Cell 
Technologies) and 100550A iPS cells were kept in Stemflex medium 
(Thermo-Fisher) at 37 ◦C in a 5% CO2 incubator. Cells were passaged 
using 0.5 mM EDTA and replated onto Cultrex (1:100 diluted in DMEM/ 
F12, Biotechne)-coated plates. 
2.2. Construction of donor plasmids 
For generating LRRK2-PGK-Puro and AARS1-PGK-Puro vectors, two 
pairs of homologous arms, LRRK2-L and LRRK2-R arms, and AARS1-L 
and AARS1-R arms, were amplified from human genomic DNA 
extracted from iPS cells of normal subject. Subsequently, they were 
cloned into the human Oct4-GFP vector (Addgene Plasmid #21153) 
replacing the Oct4-L arm-2A-GFP and Oct4-R arm and were sequenced 
to confirm correct amplification and connection. All cloning primers are 
listed below. The underlined nucleotides of LRRK2-R arm primers are 
the restriction enzyme recognition sites. The other three arms were 
cloned using NEB Hi-Fi DNA Assembly kit (New England Biolabs) due to 
the lack of suitable restriction enzyme sites. The underlined nucleotides 
therein marked the sequences of the vector. 
2.3. Gene targeting in hiPSCs 
A million of LRRK2 or 100550A iPS cells were harvested using 
Accutase (Sigma) and reverse-transfected with 1 μg of donor construct, 
12 pmol spCas9 protein (Aldevron), and 18 pmol of sgRNA (LRRK2: 5′- 
GAACTCACATCTGAGGTCAG-3′, AARS1: 5′-GGGCGTATCGGA-
CAGCTCGG-3′, Synthego), 4 μl P3000 reagent and later with 5 μl Lip-
ofectamine 3000 (Thermo-Fisher). A mixture of transfection reagents 
was added onto a Cultrex-coated well first and then followed by resus-
pended LRRK2 iPS cells or 100550A iPS cells in fresh medium with 5 μM 
Y-27632 (Stemgent). Puromycin (500 ng/ml, Sigma) was added into the 
medium three to five days after transfection. Drug-resistant cells were 
replated at low density (5,000 cells/100 mm dish) and single cell col-
onies were manually selected afterwards. Clones with both 5’ and 3’ 
insertion positive genotyping results were further expanded and the 
puromycin cassette was deleted by transient transfection of a CRE vector 
pCAG-Cre:GFP (Addgene #13776) and then plated at low density for 
single cell colonies. After a 2nd round of genotyping, positive clones 
were expanded and characterized. 
2.4. Genotyping 
Cells were collected and treated with 1x lysis buffer in PBS (For 4x 
stock: Tris-HCl pH 8 (10 mM), Triton X (2%), EDTA (4 mM) and freshly 
added Proteinase K (1%)) at 60 ◦C for 1 hr followed by 95 ◦C for 10 min. 
Genotyping was done using 1 μl of the lysis mixture as templates and two 
sets of primers to confirm both the 5′ insertion and the 3′ insertion at the 
first round. Primer set LRRK2-P1, AARS1-P1 and Puro-pA-R-P10 were 
used for confirmation of the 5′ insertion. Primer set Puro-pA-P3-2 and 
LRRK2-P4, AARS1-P4 were used for confirmation of the 3′ insertion. A 
primer set P1 and P6 was used to distinguish between WT (946 bp) and 
targeted alleles (1042 bp) at the second round of LRRK2 targeting. The 
genomic DNA amplified by the primer set LRRK2-P5 and LRRK2-P6 was 
sent for sequencing. Primer set of AARS1-P5 and AARS1-P6 was used to 
distinguish between WT (189 bp) and targeted alleles (275 bp) at the 
second round of AARS1 targeting.  











AARS1-P6 TTCATGGGCGTATCGGACAG  
Fragment Name Forward Primer Sequence Reverse Primer Sequence 
LRRK2-L arm caagcttggtaccgagctcgCCTTAATATCTAACATGATTAGGTTTATG gggttattgaatatgatcggAAGATAGAATTATGAGACAGAC 
LRRK2-R arm TTTATTGGCGCGCCCAGGATGGATAACCACTGAC TTTATTGCGGCCGCTCCCTAAAGATAGAGTGTTCC 
AARS1-L arm caagcttggtaccgagctcgAATGGCCCGATCTTGGCTC gggttattgaatatgatcggAAGCAACACCTCTTTCAGGAAC 
AARS1-R arm cctcgaagaggttcactaggGGGTAGGATTCCAAGGGAC ctctagatgcatgctcgagcTCTGTCAGAAAGGGCTTG   
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2.5. QX200 Droplet Digital PCR (ddPCR™, BIO-RAD) 
Genomic DNA was purified from each targeted 100550A cell sample 
with QIAamp DNA Mini Kit (Qiagen). A 20 µl PCR reaction mixture 
containing 50–100 ng genomic DNA, primer and probe set (designed by 
BIO-RAD, Cat# 10049047, Project dHsaMDS305174770), and QX200™ 
ddPCR™ Supermix for probes (no dUTP) (BIO-RAD) were used for 
droplet generation. Emulsified samples were then transferred to PCR 
plates according to manufacturer’s instructions. The cycling protocol 
was used with a 95 ◦C enzyme activation step for 5 min followed by 40 
cycles of a two-step cycling protocol (95 ◦C for 30 s and 55 ◦C for 1 
min). The ramp rate between these steps was 2 ◦C/second. The post 
cycling step of enzyme deactivation was set at 98 ◦C for 10 min with the 
ramp rate 1 ◦C/second. After PCR reaction, the plate was put in the 
QX200™ Droplet Reader and the events were recorded using the pro-
gram QuantaSoft. 
2.6. Off-targeting analysis 
LRRK2 and AARS1 sgRNA sequences were submitted to the website 
http://www.rgenome.net/cas-offinder/ to search for possible off- 
targeting human genomic positions with the threshold of 4 mis-
matches. All resultant genomic fragments (217 for LRRK2 and 11 for 
AARS1) were then blasted to the database: Human genomic plus tran-
script (Human G + T) at https://blast.ncbi.nlm.nih.gov/Blast.cgi. There 
was only one DNA fragment (similar to LRRK2) matching the coding 
area of human transcripts ANXA9 and one DNA fragment (similar to 
AARS1) matching the coding area of human transcripts PTX4. The cor-
responding genomic region of ANXA9 was amplified by the primers from 
both isogenic and parental LRRK2 lines (ANXA9-F: CCGTGATGG-
TACTTGTGCCT; ANXA9-R: CATCTTATGTGCATGGCGGC). The corre-
sponding genomic region of PTX4 was amplified by the primers from 
both isogenic and parental 100550A lines (PTX4-F2: ATCCACTTCGT-
GATCGGGGA; PTX4-R2: GCCCTTGCTGGCCTCAG). Then the amplicons 
were sequenced to investigate any changes for those areas. 
2.7. Immunocytochemistry 
Undifferentiated isogenic iPSCs were fixed with 4% para-
formaldehyde in 1x PBS for 20 min and blocked with 1% (v/v) bovine 
serum albumin (Sigma), 0.2% (v/v) Triton-X (SigmaAldrich), 5% 
normal donkey or goat serum in 1 × PBS for 30 min. They were then 
incubated with primary antibodies overnight at 4 ◦C, and subsequently 
labeled with fluorescence-conjugated secondary antibodies for 1 h. Im-
ages were acquired using a fluorescence microscope (Olympus Optical, 
JP/IX-71). 
2.8. STR analysis 
Short tandem repeat (STR) analysis was performed on generated 
isogenic LRRK2 and 100550A clones, together with their parental clones 
using the PowerPlex®16 System (Promega) with the detection of 16 
allele loci at the Molecular & Genomic Pathology Laboratory of Thomas 
Jefferson University Hospital. 
3. Results and discussion 
3.1. Cas9 and sgRNA can target the LRRK2 locus in the LRRK2 iPS line 
and AARS1 in the 100550A iPS line 
In order to correct the point mutation c.6055G > A of the LRRK2 
gene and c.986G > A of the ARRS1 gene, we chose the Cas9 recognition 
site in the intron closest to each mutation. For LRRK2 gene, it was in the 
intron after the exon containing the mutation. For ARRS1 gene, it was in 
Fig. 1. A stress-free strategy of correcting point mutations in patient iPS cells. A, Schematic representation of the strategy to generate a LRRK2 isogenic line with the 
corrected allele (correction of the c.6055G > A mutation of LRRK2 gene). B, Schematic representation of the strategy to generate a 100550A isogenic line with the 
corrected allele (correction of the c.986G > A mutation of AARS1 gene). 
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Fig. 2. Correction of the c.6055G > A mutation in 
LRRK2. A, Genotyping results of 48 LRRK2 isogenic 
clones after CRE cleavage of the PGK-PuroR cassette. 
The PCR primer set P1 + P6 was used to amplify the 
region covering the exon and the cutting area of the 
intron. When one allele was edited, the remaining 
loxP site made the amplicon (1042 bp) larger than 
that of the unedited allele (946 bp). The genotyping 
PCR was performed with 57 ◦C annealing tempera-
ture, 35 cycles and 1 min for extending step. The 
clone numbers are labeled for those clones having 
both alleles targeted, which expressed as one single 
up-shifted band. N marks untargeted LRRK2 cells 
expressing only the untargeted band as a negative 
control. B, Sequencing results of the G > A mutation 
area of a homozygous LRRK2 isogenic clone 4 line 
(top row). BJ line, an iPS cell line from a healthy 
subject with the WT LRRK2 gene was used as a pos-
itive control (middle row). An unedited LRRK2 
parent line was used as a negative control (bottom 
row). The arrows are pointing to the nucleotide of 
interest.   
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the intron in front of the exon. To design the sgRNA, the first 100 bp of 
the intron in human LRRK2 gene or the last 100 bp of the intron of 
AARS1 gene was analyzed to identify suitable target sites using the 
designing tool from Broad Institute (https://portals.broadinstitute. 
org/gpp/public/analysis-tools/sgrna-design). Fig. 1 describes our tar-
geting strategy for correcting the point mutation using Cas9-mediated 
homologous recombination. The donor template contains the cor-
rected LRRK2 gene fragments (A) or the corrected AARS1 gene frag-
ments (B) amplified from a normal subject iPS line, BJ, spanning the 
pGK-PuroR cassette. Following sequencing analysis and confirmation of 
the successful cloning of donor template, the RNP and donor template 
was reverse transfected into the LRRK2 or 100550A iPS cells with Lip-
ofectamine 3000. After puromycin selection, surviving cells were gen-
otyped. Nine of 45 LRRK2 clones showed positive for both the 5′
insertion (P1 + P10) and the 3′ insertion (P3-2 + P4) (Data not shown). 
These successful gene targeted clones were pooled together and were 
further transfected with a CRE vector pCAG-Cre:GFP to remove the se-
lection cassette. Then single cell colonies were manually selected and 
genotyped for the second time. From the screening results of PCR with 
primers P1 and P6, 13 of the 48 clones exhibited only an up-shifted 
band, indicating positive gene targeting of both alleles (Fig. 2A). After 
sequencing each of these up-shifted bands, we successfully confirmed 
that the correction of both alleles was made in these LRRK2 isogenic 
clones (Fig. 2B). Fifteen of 47 100550A clones demonstrated positive for 
the 3′ insertion (P3-2 + P4) (Fig. 3A). In contrast to the LRRK2 isogenic 
cells, the 100550A isogenic clones only contained one allele targeted 
while the other allele unaffected. Consistently, PCR screening with 
primer set P5 + P6 revealed no single band in each clone tested (Fig. 3B). 
To further confirm that the mutation was repaired, genomic DNA from 
the positive clones was purified and analyzed using ddPCR primers and 
two probes detecting either wild type or mutant alleles. Indeed, two 
clones tested showed no mutant allele (Fig. 3C), indicating that the 
mutation had been corrected to the WT sequence. 
The confirmed LRRK2 isogenic clones (Fig. 4 A-D) and 100550A 
isogenic clones (data not shown) were evaluated for pluripotency 
markers including Oct3/4, Sox2, Nanog, and SSEA-4 to confirm their 
cell stemness. The results showed that these isogenic clones maintained 
expression of their pluripotency markers. In addition, the genomic DNA 
of LRRK2 isogenic clone 4 and 100550A isogenic clone 9, together with 
that of the respective parent lines, was sent for Short Tandem Repeat 
(STR) analysis. The genomic DNA of both isogenic clones exhibited the 
same patterns for all sixteen markers examined as those of their 
respective parent lines (Fig. 4E), demonstrating that both lines of 
isogenic clones originated from the respective parent iPS lines. We 
checked both LRRK2 and AARS1 sgRNA for potential off-targeting 
events on the website http://www.rgenome.net/cas-offinder/. The re-
sults returned with 16 genomic regions of 3-mismatches and 201 of 4- 
mismatches for LRRK2 sgRNA, one 3-mismatch and ten 4-mismatches 
for AARS1 sgRNA. After blasting all resultant DNA sequences at NCBI, 
we found only one match (LRRK2 sgRNA sequence) to the coding area of 
ANXA9 gene and one match (AARS1 sgRNA sequence) to the coding area 
of PTX4 gene. The majority of other genomic DNA regions were not 
matching to any human transcripts with the exception of a couple of 
DNA sequences found on some transcripts but outside the coding area 
(Excel file submitted as Supplementary data). With specific primers, we 
amplified the matching ANXA9 region from both LRRK2 isogenic and 
parental iPS lines and the matching PTX4 region from both 100550A 
isogenic and parental iPS lines. After sequencing all 4 DNA fragments, 
we found no changes in the area of ANXA9 gene or PTX4 gene 
(Figure Supplementary figure 1, Figure Supplementary figure 2). Thus, 
we concluded that off-targeting events were not of major concern in 
either isogenic line. 
3.2. A more efficient way for knock-in gene targeting 
We had previously attempted to use the conventional ssODN and 
RNP approach to repair point mutations in iPS cells. Because Cas9 
editing efficiency was tightly correlated with the mutation site, we had 
to choose a sgRNA in the same exon, ideally as close as possible to the 
mutation site. This largely limited the choices of sgRNA. To identify 
Fig. 3. Correction of the c.986G > A mutation in AARS1. A, Genotyping results 
of 47 100550A clones after puromycin selection. Using the PGK-PuroR cassette 
specific primer P3-2, the clones with the amplified band (915 bp, as shown) 
were the targeted clones. Pooled cells after selection were used as a positive 
control (+). This genotyping PCR was performed with 55 ◦C annealing tem-
perature, 35 cycles and 1 min for extending step. B, Genotyping results of 5 
positive clones (Clone No: 1, 6, 7, 9, 11) after CRE removal. P5 + P6 amplifi-
cation produced two bands in each of the 5 clones, all of which were hetero-
zygotes with one targeted allele and one untargeted allele. Negative (N) control 
was unedited 100550A iPS cells. This genotyping PCR was performed with 
55 ◦C annealing temperature, 35 cycles and 30 s for extending step. C, Geno-
typing of 2 clones using ddPCR. There were only amplification from wild type 
primer set and probe in Clone 6 (C6) and Clone 9 (C9). Unedited 100550A iPS 
cells were used as a positive control, showing a similar positive number of 
events of both wild type and mutant AARS1 gene. HEK293 cells were used as a 
negative control for mutant AARS1 gene. 
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positive clones, we needed to introduce a silent mutation to construct a 
restriction enzyme site for the subsequent characterization when 
designing ssODN. In addition, genotyping hundreds of clones and per-
forming restriction enzyme reactions was tedious and time-consuming. 
Despite having screened hundreds of clones, we found only a couple 
of positive clones, all of which contained undesired additions or de-
letions at the Cas9 cleavage site causing frameshifting of the reading 
frame. We have thus developed this new strategy, which yields a much 
higher positivity rate due to the ability to engage an antibiotic selection 
(Table 1). In addition, the flexibility of the Cas9 cleavage location also 
provides a greater chance of selecting a more efficient sgRNA. Because 
Cas9 enzyme cleavage in this method occurs in an intron, we were able 
to avoid potential NHEJ events interfering with exon expression. The 
sequencing result from LRRK2 isogenic clones also showed that the 
corrected exon has no frameshifting or other mutations. We note that 
this same strategy is successful with the two targeted genes, even though 
LRRK2 isogenic lines have both alleles targeted while 100550A isogenic 
lines have only one allele targeted. Targeting efficiency may be further 
improved by varying the concentration of puromycin, the starting time 
of puromycin treatment after transfection, and the sequence context for 
designing sgRNA cleavage. It is mere coincidence that mutations in our 
two patient-derived iPSC lines are both G > A. Since the correction is 
introduced on a homologous arm, we predict that this strategy should 
work in other point mutations or frameshifting. It is noteworthy that our 
two mutations happen to be relatively close to a nearby intron making it 
possible to find a specific and efficient gRNA for Cas9 cutting. For mu-
tations of intronless coding regions or mutations where no nearby in-
trons can be found, our method will probably not work. In conclusion, 
compared to the traditional approach for knock-in gene targeting, this 
new strategy provides the possibility of antibiotic selection, flexibility of 
sgRNA design, avoids possible NHEJ events and therefore has the po-
tential to advance the use of iPS lines as disease models. 
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